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Objective: The sensitivity to change of quantitative analysis of cartilage in knee osteoarthritis using
magnetic resonance imaging (MRI) is compromised by the spatial heterogeneity of cartilage loss. We
explore whether extended (medialelateral) “ordered values” (OVs) are superior to conventional
approaches of analyzing subregional cartilage thickness loss and to radiography, in differentiating rates
of progression in knees with and without joint space narrowing (JSN).
Methods: 607 Osteoarthritis Initiative (OAI) participants (308 without and 299 with baseline JSN at
baseline) were studied over 12 months. Subregional femorotibial cartilage loss was determined in all
knees, and changes in minimum joint space width (mJSW) in a subset of 290 knees. Subregional
thickness changes in medial and lateral tibial and femoral cartilages were sorted in ascending order
(OV1-16). AWilcoxon rank-sum test was used to compare rates of change in knees with and without JSN.
Results: JSN-knees displayed greater cartilage loss than those without JSN, with minimal P-values of
0.008 for femorotibial subregions, 3.3 104 for medial OV1, and 5.4 107 for extended (medial and
lateral) OV1. mJSWmeasurements (n¼ 290) did not discriminate between longitudinal rates of change in
JSN vs no-JSN knees (P¼ 0.386), whereas medial OV1 (P¼ 5.1 104) and extended OV1 did (P¼ 2.1
105).
Conclusion: Extended OVs showed higher sensitivity to detecting differences in longitudinal rates of
cartilage loss in knees with and without baseline JSN than anatomical (sub)regions and radiography. The
OV technique also circumvents challenges of selecting particular regions “a priori” in clinical trials and
may thus provide a powerful tool in studying risk factors or treatment efﬁcacy in osteoarthritis.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.to: W. Wirth, Institute of
rgasse 21, A5020 Salzburg,
002-1249.
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s Research Society International. PIntroduction
Quantitative MRI has emerged as a powerful tool for elucidating
the natural progression and patho-physiology of osteoarthritis
(OA), for identifying risk factors of OA, and for evaluating the effect
of structure or disease modifying OA drugs (DMOADs)1e4.
However, recent studies employing MRI technology reported thatublished by Elsevier Ltd. All rights reserved.
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amount of spatial heterogeneity between femorotibial joint
compartments (medial, lateral), plates (tibia, femur), and sub-
regions5e12. Previous studies hypothesized that cartilage loss in
knee OA may preferentially occur in certain subregions of the
femorotibial joint5,13, but recent evidence suggests that the MRI-
based sensitivity to change for anatomically deﬁned subregions is
not relevantly improved when compared to the analysis of total
cartilage plates: Although central femorotibial subregions gener-
ally displayed greater rates of change than peripheral ones5,10, the
intersubject variability of central changes was also higher than for
total cartilage plates6,10. Potential explanations for this observation
are that only some knees show preferential central changes, and
that once the cartilage is lost centrally, no further progression can
be observed in central subregions. Moreover, a recent study
showed that local meniscus lesions (in the anterior or posterior
horn or body) are associated with higher rates of progression in
immediately adjacent tibial cartilage subregions14. The fact that
meniscal lesions are frequent15 and strongly related to OA
progression16,17 provides a potential explanation, why rates of
cartilage loss display strong spatial heterogeneity in peripheral
subregions in OA.
As a potential solution to this challenge, Buck et al.18 recently
proposed a strategy for more efﬁciently measuring cartilage loss in
OA by removing the link between magnitudes and locations of
regional thickness changes in MRI. The authors showed that
determining OVs of subregional change within the MEDIAL femo-
rotibial compartment of each knee (medial OV approach) and then
ranking the subregional change according to its magnitude,
provided improved discrimination of cartilage loss between
changes in healthy subjects and participants with MEDIAL radio-
graphic OA. However, in general OA populations, a problem arises
from the fact that some knees show preferential changes in the
medial and others in the lateral femorotibial compartment, partly
caused by differences in limb alignment17,19e22. In clinical trials, this
can be circumvented by only selecting knees with either medial or
lateral disease but this substantially increases the effort and cost
involved in participant selection and also limits generalizability.
Moreover, a recent study investigating the potential structure
modifying effects of licofelone and naproxen23 selected patients
with MEDIAL femorotibial radiographic change and deﬁned the
MEDIAL compartment cartilage volume changes as the primary
efﬁcacy outcome measure. Although the primary outcome was
reached in this study, the protective effect of licofelone was more
evident in the lateral than in the medial compartment.
The objectives of the current study were:
1) to extend the proposed OV approach18 to not only include
medial but also lateral femorotibial subregions, in order to
account for knees with both medial and lateral (radiographic)
OA
2) to apply this approach to the analysis of cartilage thickness
changes (i.e., cartilage loss) as a measure of OA progression in
a large subset of knees with and without radiographic JSN at
baseline, provided by the OAI9,24e26.
3) to examine whether the extended OV approach shows
a greater statistical sensitivity to differences in longitudinal
cartilage changes between knees with and without baseline
JSN than
a) the medial OV approach,
b) the region-based approach, and
c) the mJSW approach, using radiography.
4) to further explore the statistical speciﬁcity of the extended OVs
approach in relation to the region-based approach and the
medial OVs approach.Methods
Study participants
The study was based on the analysis of right knees from the OAI
(public use data sets 0.2.2 [baseline clinical], 0.E.1 [baseline images],
and 1.E.1 [12 month follow-up images]) and was conducted in
compliancewith the ethical principles derived from the Declaration
of Helsinki and in compliancewith local Institutional Review Board,
informed consent regulations, and International Conference on
Harmonization Good Clinical Practices Guidelines. Knees were
randomly selected based on (1) ascending OAI ID and (2) the
“calculated” Kellgren and Lawrence grades (cKLG), derived from
osteophyte and radiographic JSN readings performed at baseline at
the OAI clinical sites, according to the Osteoarthritis Research
Society International (OARSI) atlas27. For the current study, we
selected 607 knees with deﬁnite osteophytes and with either
moderate JSN (299 knees with Osteoarthritis Research Society
International (OARSI) grade 1 or 2:113 males, 186 females)27 or
without JSN at baseline (308 knees: 111 men, 197 females), because
previous studies have shown a higher rate of cartilage thickness
changes in knees with advanced radiographic OA (i.e., with baseline
JSN) than in knees with less advanced radiographic OA (i.e., without
baseline JSN)7,8,28,29. In this context it is worth noticing that
although JSN is clearly associated with cartilage thickness loss30,
there is substantial variability between OA participants, and JSN is
additionally inﬂuenced by meniscus extrusion and degeneration31.
For 290 of the above knees, longitudinal (quantitative)
measurements ofmedial minimum joint spacewidth (mJSW)32 have
recently been made available by the OAI (J Duryea, Brigham and
Womens Hospital, Boston, MA, USA) based on ﬁxed ﬂexion radio-
graphs33 obtained at baseline and at 12month follow-up. From these
147 displayed baseline JSN in site readings and 143 did not.
MR image analysis
Double oblique, coronal MR images were acquired at baseline
and 12 month follow-up, using a fast low angle shot sequence with
water excitation (FLASHwe), 3 Tesla MR scanners (Siemens Mag-
netom Trio, Erlangen, Germany) and quadrature transmit-receive
knee coils (USA Instruments, Aurora, OH, USA); the imaging
protocol and quality control procedures have been described in
detail in previous publications9,24,25,34 (Fig. 1). After a quality
control step (MH) at the image analysis center (Chondrometrics
GmbH, Ainring, Germany), the data were analyzed by seven
readers, each with more than 3 years experience in cartilage
segmentation. The segmentationwas performed for paired baseline
and 12 month follow-up images, the readers being blinded to the
order of the acquisition as well as to the clinical and radiographic
data. The subchondral bone area (tAB) and the cartilage surface
area (AC) were traced manually in the medial (MT) and lateral tibia
(LT) and in the central, weight-bearing part of the medial femoral
condyle (cMF) and central, weight-bearing part of the lateral
femoral condyle (cLF). All segmentations were quality controlled by
an expert reader (SM) and were corrected by the readers, if
necessary. The mean cartilage thickness over the total subchondral
bone area, including denuded areas, (ThCtAB) was determined in
cartilage plates (MT, LT, cMF and cLF) and compartments (medial
femorotibial compartment¼MFTC¼MTþcMF and lateral femo-
rotibial compartment¼ LFTC¼ LTþcLF). Subregional thickness
was determined in the central, external, internal, anterior, and
posterior aspect of MT and LT, and in the central, external, and
internal aspects of cMF and cLF, as described previously13 (Fig. 1).
The central subregions were set to cover 20% of the tAB in MT and
LT, and 33% in cMF and cLF.
Fig. 1. Double oblique coronal fast low angle shot (FLASH) MR image with water excitation showing the regions of interest analyzed: MFTC (¼MTþ cMF), LFTC (¼LTþcLF). The top
part of the ﬁgures shows a reconstruction of the weight-bearing parts of the femoral condyles (cMF and cLF) and the lower part a reconstruction of the tibiae (MT and LT).
(cjejijajp¼ centraljexternaljinternaljanteriorjposterior subregion of MT or LT. cjeji¼ centraljexternaljinternal subregion of the central part of cMF or cLF).
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Differences in subject characteristics between subjects with and
without baseline JSN were assessed using two-sided t-tests. All
longitudinal analyses including only MRI data were applied to the
full cohort (n¼ 607), whereas the comparison between longitudinal
MRI and radiographic mJSW were performed for the subcohort
(n¼ 290). As a measure of progression, the mean change (MC) and
the standard deviation (SD) of the change in mm for ThCtAB (MRI)
and mJSW (radiography) between baseline and 12 month follow-up
were determined. Percent changes were derived by relating the MC
observed across a group to the respective average baseline value. The
differences between the changes in the compared groups were
described by the mean difference and 95% conﬁdence intervals. The
OV approach18 was extended to comprise all 16 subregions in the
femorotibial joint (ﬁve in MT and LT, and three in cMF and cLF,
respectively): Subregional changes (in ThCtAB) within each knee
were sorted in ascending order, i.e., the subregion showing the most
negative change (decrease in ThCtAB) was assigned to extended
ordered value (eOV) 1, and the value of the subregion showing the
smallest negative or greatest positive change (increase in ThCtAB)
was assigned to eOV 16 (Fig. 2).
To compare the rates of progression (cartilage thickness loss) in
no-JSN and JSN knees, the MC and SD were evaluated for each
compartment, cartilage plate and subregion as well as for the
medial (mOV) and eOV approach (medial and lateral) (mOV 1e8,
and eOV 1e16, respectively). The non-parametric Wilcoxon rank-
sum test was used to determine whether the changes differed
signiﬁcantly between the JSN and the no-JSN knees, because the
longitudinal changes may not be normally distributed.
Because the chance of at least one type I error increases with the
number of parallel comparisons, and because the number of
parallel comparisons differed between compartments (two
measures), cartilage plates (four measures), subregions
(16 measures), and OVs (eight measures for mOVs, 16 measures for
eOVs), the individual test signiﬁcance levels were adjusted for the
number of (parallel) comparisons (BonferronieDunn correction for
overall signiﬁcance level¼ 0.05): P< 0.025 for two compartments;
P< 0.0125 for four plates, P< 0.003125 for 16 subregions,Fig. 2. Graph showing the OVs approach: (A) The top spread sheet shows the results (change
example OAI subjects. (B) The rates of change are ranked according to their magnitude in the
the orders in the bottom spread sheet. The subregionwith the most negative change (decreas
most negative change assigned to order two, and the subregion showing the smallest negat
differently located subregions contribute to order one in the four subjects shown.P< 0.00625 for eight mOVs and P< 0.003125 for 16 eOVs. The
signiﬁcance levels were adjusted within each hierarchical category
of joint compartments (n¼ 2), cartilage plates (n¼ 4) or cartilage
subregions (n¼ 16), but not across these categories, because lower
hierarchical levels are contained in (and correlated with) higher
levels.
To further explore the statistical sensitivity of the different MRI-
measures, the bootstrapping approach35 was employed to simulate
10,000 “new” samples derived from the original study cohort by
sampling the observed changes with replacement. The sample sizes
(no-JSN and JSN) were kept constant.
The speciﬁcity of all measures is theoretically ﬁxed during the
testing procedure, as it corresponds to the level of false positives
(signiﬁcance level a), which is stated a priori. This is a theoretical
assumption, however, and it is worthwhile to assess whether new
testing procedures match the desired signiﬁcance level.
A randomization test assigning the observed changes in the JSN
cohort for 10,000 times randomly without replacement to two
subcohorts was employed for this purpose. For both the boot-
strapping and the randomization method, the percentage of
P-values below the unadjusted and the adjusted level of signiﬁ-
cance, and the median and SD of P-values were determined using
the Wilcoxon rank-sum test, to assess the test characteristics of
power (sensitivity) and signiﬁcance level (speciﬁcity) for each
measure.
Results
The no-JSN participants displayed a marginally lower age
(60.6 9.0 vs 64.2 9.4 years, P¼ 7.5E6), body height
(166.3 8.7 cm vs 168.2 9.4 cm; P¼ 0.014), and body weight
(81.615.2 kg vs 84.416.8 kg; P¼ 0.022) than the JSN partici-
pants. The difference in BMI (29.4 4.6 kg/m2 vs 29.8 4.7 kg/m2),
however, was not statistically signiﬁcant (P¼ 0.199). In the sub-
cohort with both MRI and JSW readings (n¼ 290), age was signif-
icantly different between knees with baseline JSN vs no-JSN
(P¼ 0.013), but there were no signiﬁcant differences in height
(P¼ 0.10), weight (P¼ 0.16), and BMI (P¼ 0.56) between JSN and
no-JSN knees.in cartilage thickness [ThCtAB] in mm) in the femorotibial subregions (see Fig. 1) of four
middle spread sheet. (C) The magnitudes of the changes (in mm) are then attributed to
e in ThCtAB) in each subject is assigned to order one, the subregion showing the second
ive or the greatest positive change (increase in ThCtAB) assigned to order 16. Note that
Table I
Femorotibial compartments and cartilage plates: change in cartilage thickness (ThCtAB) over 12 months in knees without baseline JSN (no-JSN, n¼ 308) and with baseline JSN
(JSN, n¼ 299)
no-JSN JSN Between-group P-value SL
MC [mm] SD [mm] MC [%] MC [mm] SD [mm] MC [%] DIFF [mm] CI [mm]
MFTC 12 100 0.3 40 128 1.2 28 10/46 0.003* 0.025
LFTC 8 81 0.2 29 126 0.8 21 4/38 0.090 0.025
MT 2 46 0.1 10 55 0.6 8 0/16 0.027 0.013
cMF 11 76 0.6 30 96 1.8 20 6/33 0.007* 0.013
LT 10 48 0.5 21 70 1.1 11 1/20 0.119 0.013
cLF 2 58 0.1 7 84 0.4 10 2/21 0.201 0.013
MC in mm or %, DIFF¼mean difference between changes, CI¼ 95% conﬁdence intervals of differences between changes (lower/upper limit), SL¼ signiﬁcance level after
BonferronieDunn correction: The signiﬁcance (P-value) of the differences between changes in JSN and no-JSN knees was computed using non-parametric Wilcoxon rank-sum
tests and is reported in the table without adjustment for multiple comparisons. Compartments and cartilage plates showing signiﬁcant differences after BonferronieDunn
correction (P< 0.025 for compartments, P< 0.0125 for cartilage plates) are marked with *.
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rotibial compartments varied from0.1% in LFTC of no-JSN knees to
1.2% in MFTC in JSN knees (Table I). The level of statistical
signiﬁcance of the differences in progression between no-JSN and
JSN knees was higher for MFTC (P¼ 0.003 without correction for
multiple testing) than for LFTC (P¼ 0.090). When analyzing carti-
lage plates, the rates of change (Table I) were greater for the femur
than for the tibia medially, but were greater for the tibia than for
the femur laterally (Table I). Differences in cartilage thickness loss
between JSN vs no-JSN knees were most apparent in the medial
femur (cMF; P¼ 0.007 without correction; Table I).
When analyzing femorotibial subregions, the greatest MCs were
observed in the central aspect of the weight-bearing femur medi-
ally (ccMF) and in the central aspect of the tibia laterally (cLT)
(Table II). cLT was also the subregion to best discriminate the rate of
change between no-JSN and JSN knees (P¼ 0.016 without correc-
tion) laterally, whereas the level of signiﬁcance for cartilage thick-
ness loss in JSN vs no-JSN knees in the medial compartment was
higher for the external aspect of the weight-bearing femur (ecMF;
P¼ 0.008), the external aspect of the tibia (eMT; P¼ 0.009) and the
posterior aspect of the tibia (eMT; P¼ 0.022) than for ccMF
(P¼ 0.030) (Table II). In all of the eight medial, and in 13 of the
16 total (medial and lateral) subregions, the rates of cartilage
thickness loss were greater for JSN than for no-JSN knees (Table III).
When analyzing mOVs in the total cohort (n¼ 607, Table III),
four showed negative changes (cartilage thinning or loss), and four
positive changes (cartilage thickening) in the no-JSN knees,Table II
Femorotibial subregions: change in cartilage thickness (ThCtAB) over 12 months in knee
no-JSN JSN
MC [mm] SD [mm] MC [%] MC [mm] SD [mm
cMT 8 91 0.3 24 103
eMT 6 80 0.4 21 88
iMT 4 65 0.2 8 70
aMT 4 64 0.2 3 69
pMT 1 57 0.1 8 61
ccMF 23 122 1.0 49 150
ecMF 4 84 0.2 22 105
icMF 7 69 0.4 22 86
cLT 21 98 0.7 49 139
eLT 6 67 0.3 16 81
iLT 16 70 0.8 29 100
aLT 0 61 0.0 5 75
pLT 11 91 0.6 11 105
ccLF 2 85 0.1 14 127
ecLF 4 71 0.3 6 90
icLF 0 69 0.0 4 85
The signiﬁcance (P-value) of the differences between changes in JSN and no-JSN knees w
table without adjustment for multiple comparisons. None of the femorotibial subregionswhereas ﬁve showed negative changes and three positive changes
in the JSN knees. The most signiﬁcant difference in the rate of
cartilage change between no-JSN and JSN knees was observed in
OV1 (P¼ 3.29104). mOV1 through three attained smaller
P-values than found for any anatomical subregion, cartilage plate,
or compartment (Tables IeIII).
With the extended (medial and lateral) approach, eight OVs
showed negative changes and eight positive changes in no-JSN
knees, whereas nine showed negative changes and seven positive
changes in JSN knees (Table III). The most signiﬁcant differences in
the rate of cartilage change between JSN and no-JSN knees were
again observed for OV1 (P¼ 5.38 107). eOVs 1 through 7 attained
smaller P-values than found for any anatomical subregion, cartilage
plate, or compartment (Tables IeIII) and OV1 through OV6 for
the extended approach displayed a smaller P-value than any OV for
the medial approach. The frequency with which the subregions
represented eOV1 was not uniformly distributed and ranged
between 2.6% (eMT, pMT & ecMF) and 14.6% (cLT) in the no-JSN
sample and between 1.7% (aMT) and 16.1% (ccMF) in the JSN
sample.
When correcting the observed P-values for multiple parallel
testing at the compartment (two compartments) or plate level (four
plates), a signiﬁcantly different rate of change between JSN and no-
JSN knees was observed in MFTC and cMF. In the 16 subregions,
none of the changes differed signiﬁcantly between JSN and no-JSN
knees after BonferronieDunn correction. In contrast, three of the
eight mOVs, and seven of the 16 eOVs differed signiﬁcantlys without baseline JSN (no-JSN, n¼ 308) and with baseline JSN (JSN, n¼ 299)
Between-group P-value SL
] MC [%] DIFF [mm] CI [mm]
1.0 16 0/31 0.042 0.003
1.6 15 1/28 0.009 0.003
0.4 4 7/15 0.331 0.003
0.2 1 10/11 0.775 0.003
0.5 9 0/18 0.022 0.003
2.5 26 4/48 0.030 0.003
1.7 19 4/34 0.008 0.003
1.2 15 2/27 0.031 0.003
1.8 28 9/47 0.016 0.003
1.1 11 1/23 0.270 0.003
1.7 13 1/27 0.220 0.003
0.3 5 5/16 0.235 0.003
0.6 0 16/16 0.715 0.003
0.6 15 2/33 0.123 0.003
0.4 10 3/23 0.279 0.003
0.3 5 8/17 0.447 0.003
as computed using non-parametric Wilcoxon rank-sum tests and is reported in the
showed signiﬁcant differences after BonferronieDunn correction (P< 0.0031).
Table III
Femorotibial orders (OV approach): change in cartilage thickness (ThCtAB) over 12months in knees without baseline JSN (no-JSN, n¼ 308) andwith baseline JSN (JSN, n¼ 299)
no-JSN JSN Between-group P-value SL
MC [mm] SD [mm] MC [%] MC [mm] SD [mm] MC [%] DIFF [mm] CI [mm]
Medial approach
mOV 1 98 101 5.0 125 125 7.0 28 9/46 3.3E4* 6.3E3
mOV 2 62 80 3.6 78 85 4.8 16 2/29 0.004* 6.3E3
mOV 3 33 50 1.9 50 70 3.0 17 7/27 0.001* 6.3E3
mOV 4 13 45 0.7 26 60 1.6 12 4/21 0.009 6.3E3
mOV 5 6 42 0.4 4 52 0.2 10 3/18 0.011 6.3E3
mOV 6 26 42 1.5 17 51 1.0 9 1/16 0.016 6.3E3
mOV 7 48 46 2.7 41 59 2.4 7 1/16 0.032 6.3E3
mOV 8 81 52 4.5 76 65 4.5 5 4/15 0.198 6.3E3
Extended approach:
eOV 1 136 104 6.5 181 144 9.4 45 25/65 5.4E7* 3.1E3
eOV 2 97 80 5.3 126 95 7.3 29 15/43 9.6E7* 3.1E3
eOV 3 69 50 3.7 95 78 5.4 27 16/37 5.7E7* 3.1E3
eOV 4 53 43 2.8 73 61 4.2 20 12/29 1.5E5* 3.1E3
eOV 5 40 40 2.1 57 55 3.2 17 9/25 9.5E5* 3.1E3
eOV 6 29 39 1.5 43 50 2.5 15 8/22 2.2E4* 3.1E3
eOV 7 19 37 1.0 31 45 1.8 12 6/19 0.001 3.1E3
eOV 8 9 35 0.5 19 43 1.1 10 4/16 0.006 3.1E3
eOV 9 1 34 0.0 7 42 0.4 8 2/14 0.032 3.1E3
eOV 10 10 32 0.5 4 43 0.2 6 0/12 0.099 3.1E3
eOV 11 21 32 1.2 16 43 0.9 4 2/10 0.340 3.1E3
eOV 12 31 31 1.7 28 43 1.7 3 3/9 0.786 3.1E3
eOV 13 44 33 2.4 42 44 2.5 2 4/8 0.721 3.1E3
eOV 14 59 37 3.2 61 48 3.5 1 8/5 0.369 3.1E3
eOV 15 79 43 4.2 81 55 4.7 1 9/6 0.557 3.1E3
eOV 16 112 55 5.8 116 71 6.5 4 14/6 0.505 3.1E3
The signiﬁcance (p-value) of the differences between changes in JSN and no-JSN knees was computed using non-parametric Wilcoxon rank-sum tests and is reported in the
table without adjustment for multiple comparisons. mOVs and eOVs showing signiﬁcant differences after BonferronieDunn correction (P< 0.0063 for medial, P< 0.0031 for
eOVs) are marked with *. OVs were computed from subregional changes in 8 (medial approach)/16 (extended approach) subregions in the medial (medial approach)/medial
and lateral (extended approach) femorotibial joint. OV 1¼ subregion showing the most negative change (decrease in ThCtAB) in each subject, OV 2¼ subregion showing the
second most negative change, ..OV 8 (medial approach)/16 (extended approach)¼ subregion showing the smallest negative or the greatest positive change (increase in
ThCtAB).
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changes (cartilage thickening) displayed signiﬁcant differences
between JSN and no-JSN knees after BonferronieDunn correction,
both for the medial and for the extended approach.
In the subcohort of knees with quantitative measurement of the
radiographic mJSW (n¼ 290), the rate of change in mJSW did not
differ signiﬁcantly (P¼ 0.386) between JSN and no-JSN knees
(Table IV). mOV1 (P¼ 5.12104) and the eOV1 (P¼ 2.10105),
however, signiﬁcantly discriminated rates of progression between
JSN and no-JSN knees even after BonferronieDunn correction for
multiple testing.
The percentage of P-values below the adjusted signiﬁcance level
of 0.05 was higher for the ﬁrst ﬁve eOVs (range 80.1%e96.7%) than
for any of the other measures (range 0.4%e77.6%), when comparing
changes of JSN vs no-JSN knees using the bootstrapping method.Table IV
Change in minimal medial joint space width (mJSW), medial compartment cartilage thick
knees without baseline JSN (n¼ 143) and with baseline JSN (n¼ 147) for which longitud
no-JSN JSN
MC [mm] SD [mm] MC [%] MC [mm] SD [mm
mJSW 81 575 1.7 129 654
MFTC 18 113 0.5 59 142
MT 4 50 0.2 12 59
cMF 14 83 0.7 47 110
mOV 1 102 107 5.1 146 152
eOV 1 140 110 6.4 198 169
The signiﬁcance (P-value) of the differences between changes in JSN and no-JSN knees w
table without adjustment for multiple comparisons. Parameters showing signiﬁcant differ
cartilage plates, P< 0.0063 for medial, and P< 0.0031 for eOVs) are marked with *. mOV1
each subject. eOV1¼ subregion showing the most negative change (decrease in ThCtAB)The distribution of P-values varied from unimodal distributions for
parameters showing a high percentage of P-values below the
signiﬁcance level (e.g., eOV 1e3) to an approximate uniform
distribution (e.g., aMT, see Table V & Fig. 3). The median P-value
obtained from the within-group randomization (Table V) was
between 0.49 and 0.51 with a SD of 0.29 for all measures. All
distributions of P-values approximated the uniform distribution
(see Table V & Fig. 3).
Discussion
In this study we tested the hypothesis that an eOVs approach
is superior to conventional approaches of measuring subregional
MRI-based cartilage thickness loss, and to radiography, in
longitudinally differentiating rates of progression in knees withness, and OVs of subregional cartilage thickness (ThCtAB) change over 12 months in
inal mJSW and the MRI outcomes were available
Between-group P-value SL
] MC [%] DIFF [mm] CI [mm]
3.3 48 94/190 0.386 0.050
1.7 41 11/70 0.007* 0.025
0.7 8 5/21 0.160 0.013
2.7 32 10/55 0.002* 0.013
8.2 43 13/74 5.1E4* 6.3E3
10.4 58 25/91 2.1E5* 2.9E3
as computed using non-parametric Wilcoxon rank-sum tests and is reported in the
ences after BonferronieDunn correction (P< 0.025 for compartments, P< 0.0125 for
¼ subregion showing the most negative change (decrease in ThCtAB) in the MFTC of
in the medial or the lateral femorotibial compartment of each subject.
Table V
Percentage of P-values less than 0.05 computed using the bootstrapping method between knees without and with JSN and computed using a randomization of knees with JSN
aSL Bootstrap (no-JSN vs JSN knees) Randomization (JSN knees)
% (P< SL) % (P< aSL) Median SD % (P< SL) % (P< aSL) Median SD
Regional approach
MFTC 0.0250 84.7 76.9 2.6E-03 0.09 4.9 2.6 0.50 0.29
LFTC 0.0250 34.8 25.4 0.11 0.27 4.9 2.4 0.50 0.29
MT 0.0125 60.4 39.4 0.03 0.19 4.8 1.2 0.50 0.29
cMF 0.0125 77.8 58.6 0.01 0.12 5.0 1.2 0.50 0.29
LT 0.0125 29.8 14.5 0.15 0.28 5.1 1.3 0.49 0.29
cLF 0.0125 22.9 10.6 0.22 0.29 4.7 1.1 0.50 0.29
cMT 0.0031 50.0 16.4 0.05 0.22 5.0 0.3 0.50 0.29
eMT 0.0031 75.0 37.6 0.01 0.13 4.8 0.3 0.50 0.29
iMT 0.0031 16.7 2.5 0.31 0.30 4.6 0.2 0.50 0.29
aMT 0.0031 5.8 0.4 0.49 0.29 4.9 0.3 0.50 0.29
pMT 0.0031 60.1 22.9 0.03 0.18 5.0 0.3 0.50 0.29
ccMF 0.0031 60.7 23.9 0.03 0.19 5.1 0.4 0.50 0.29
ecMF 0.0031 76.7 39.8 0.01 0.12 5.3 0.3 0.49 0.29
icMF 0.0031 59.0 22.3 0.03 0.20 4.9 0.2 0.51 0.29
cLT 0.0031 65.7 28.0 0.02 0.17 4.9 0.4 0.50 0.29
eLT 0.0031 17.7 2.7 0.28 0.30 4.9 0.4 0.50 0.29
iLT 0.0031 19.7 3.1 0.26 0.30 4.4 0.3 0.50 0.29
aLT 0.0031 23.3 4.3 0.21 0.29 5.5 0.4 0.50 0.29
pLT 0.0031 7.6 0.8 0.46 0.30 5.0 0.3 0.50 0.29
ccLF 0.0031 32.3 7.5 0.13 0.27 4.9 0.2 0.50 0.29
ecLF 0.0031 18.9 3.2 0.27 0.30 5.0 0.4 0.50 0.29
icLF 0.0031 10.7 1.2 0.40 0.30 4.6 0.3 0.51 0.29
mOVs
mOV 1 0.0063 93.7 77.6 4.5E-04 0.05 5.1 0.6 0.50 0.29
mOV 2 0.0063 79.9 52.6 4.9E-03 0.11 5.1 0.6 0.50 0.29
mOV 3 0.0063 89.8 69.8 1.2E-03 0.07 5.3 0.6 0.50 0.29
mOV 4 0.0063 73.7 44.4 0.01 0.14 4.9 0.6 0.50 0.29
mOV 5 0.0063 73.1 43.9 0.01 0.14 4.9 0.7 0.50 0.29
mOV 6 0.0063 70.7 40.6 0.01 0.15 4.7 0.6 0.50 0.29
mOV 7 0.0063 61.9 31.9 0.02 0.18 4.8 0.6 0.49 0.29
mOV 8 0.0063 30.4 10.0 0.15 0.28 5.0 0.7 0.50 0.29
eOVs
eOV 1 0.0031 99.8 96.7 1.9E-06 0.01 5.0 0.3 0.49 0.29
eOV 2 0.0031 99.7 96.2 2.2E-06 0.01 4.9 0.2 0.49 0.29
eOV 3 0.0031 99.9 97.4 1.0E-06 0.00 5.1 0.3 0.49 0.29
eOV 4 0.0031 98.9 90.0 2.1E-05 0.02 5.0 0.3 0.49 0.29
eOV 5 0.0031 96.7 80.1 1.4E-04 0.03 5.0 0.2 0.50 0.29
eOV 6 0.0031 94.8 74.0 3.1E-04 0.05 5.2 0.3 0.49 0.29
eOV 7 0.0031 90.2 62.2 1.1E-03 0.07 5.1 0.3 0.50 0.29
eOV 8 0.0031 75.3 38.5 0.01 0.13 5.2 0.4 0.50 0.29
eOV 9 0.0031 54.9 19.3 0.03 0.20 4.9 0.3 0.49 0.29
eOV 10 0.0031 36.5 8.8 0.10 0.27 5.1 0.3 0.50 0.29
eOV 11 0.0031 17.0 2.2 0.29 0.30 5.0 0.3 0.50 0.29
eOV 12 0.0031 6.1 0.4 0.47 0.29 5.0 0.3 0.50 0.29
eOV 13 0.0031 7.8 0.7 0.45 0.30 4.7 0.3 0.50 0.29
eOV 14 0.0031 10.8 1.4 0.39 0.30 5.0 0.3 0.51 0.29
eOV 15 0.0031 6.8 0.6 0.46 0.29 4.9 0.3 0.50 0.29
eOV 16 0.0031 7.6 0.7 0.45 0.30 4.8 0.3 0.50 0.29
SL¼ Signiﬁcance level (0.0). aSL¼ Signiﬁcance level (0.05) adjusted for multiple comparisons. % (P< SL)¼ Percentage of P-values less than the signiﬁcance level. %(P< aSL)¼
Percentage of P-values less than the adjusted signiﬁcance level (aSL). Median¼Median P-value obtained from the P-values computed after each of the 10,000 bootstrapping
runs (no-JSN vs JSN knees) and after each of the 10,000 randomization runs (JSN knees vs JSN knees). SD of the P-values. All P-values were computed using non-parametric
Wilcoxon rank-sum tests. OVs were computed from subregional changes in 8 (medial approach: mOV 1e8)/16 (extended approach: eOV 1e16) subregions in the medial
(medial approach)/medial and lateral (extended approach) femorotibial joint.
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suggested that knees with radiographic JSN at baseline display
greater rates of cartilage loss than those without JSN7,8,12, this
hypothesis was tested in JSN vs no-JSN knees from the OAI. The
primary purpose of the study was to explore the gain in sensi-
tivity to differences between groups, when using the eOV
approach to differentiate structural OA progression in two groups
with previous evidence of differences in the rate of cartilage loss.
It is important to note that this approach is not limited to the
question of difference in cartilage loss of JSN vs no-JSN knees, but
may also be applied to elucidate the impact of other risk factors
on OA progression, or to evaluate the effect of a potential
DMOAD.The ﬁndings show that the removal of the link between the
magnitude of change and its speciﬁc location (in any given knee)
is highly effective in improving the sensitivity in detecting
signiﬁcant differences in the rates of progression between
groups. Particularly in a cohort that includes knees with both
medial and lateral radiographic OA (as in the current study), this
may be attributed to the fact that changes occur only in some
(but not in other) subregions, and that changes across different
subregions (in the same or in the contralateral compartment) are
not generally positively correlated. Radiography provides
a composite measure of cartilage thickness, meniscus integrity
and extrusion31 and is unable to reveal the spatial heterogeneity
of cartilage thickness changes, whereas MRI provides the
Fig. 3. Graphs showing the distribution of P-values obtained from (A) the bootstrapping method and from (B) the randomization of changes in JSN knees. The distribution is shown
for the entire MFTC and LFTC, the anterior subregion of the medial tibia (aMT), the mOV1, and the eOV1, eOV16.
W. Wirth et al. / Osteoarthritis and Cartilage 19 (2011) 689e699696
W. Wirth et al. / Osteoarthritis and Cartilage 19 (2011) 689e699 697opportunity to capture change in multiple subregions. However,
particular statistical approaches (i.e., OVs) are required, in order
to fully exploit the value of subregional information that is
provided. A potential downside of the eOV (medial and lateral)
approach proposed is the need to perform segmentations in
both femorotibial compartment, which extends analysis time
and cost.
In the absence of an external gold standard, the results obtained
with the bootstrapping method support the sensitivity levels
observed for the different methodologies. The observed percentage
of P-values below the deﬁned signiﬁcance level for the between-
group differences was higher for the ﬁrst ﬁve eOVs than for any
other measure. This conﬁrms the higher sensitivity to between-
group differences for eOVs, even when adjusting for multiple
comparisons.
The randomization of the changes within the group of JSN
knees showed a similar speciﬁcity of all measures used in this
study, as the P-values were almost uniformly distributed for all
measured parameters and the median and SD observed for each
parameter closely approximated the theoretical median (0.5) and
SD (0.289) of a uniform distribution between 0 and 1. Because
the number of false positives (percentage of P-values smaller
than the signiﬁcance level) was consistent with the deﬁned false
positive rate for all of the measures, the medial and the eOVs can
be assumed to display a similar speciﬁcity as the regional
approach.
A general challenge in designing a clinical trial in OA (either for
identifying risk factors or for testing DMOADs) is to determine
a primary outcome parameter (i.e., ThCtAB in a compartment,
plate or subregion) “a priori”. This is particularly true for MRI,
which due to its three-dimensional nature allows for the analysis of
changes (either quantitatively or semi-quantitatively) in a multi-
tude of articular tissues, and also in a great number of anatomical
subregions36. Previous studies employing quantitative (sub)
regional cartilage analysis with MRI observed that longitudinal
changes of cartilage thickness display substantial spatial hetero-
geneity between knees, and also found variable results between
studies in reasonably sized cohorts37. Another recent study was
unable to identify signiﬁcant change in ThCtAB over relatively short
observation periods of 3 and 6 months, despite the fact that the
“most progressive” medial subregion (ccMF) was selected as an
outcome, and albeit only knees with medial radiographic disease
and several risk factors of OA progression were selected38. To
overcome the limited sensitivity to change of quantitative MRI (and
radiography) due to spatial heterogeneity of cartilage loss, Buck
et al.18 proposed an OV approach of subregional changes in MEDIAL
compartment cartilage thickness. This approach used only the
medial compartment because it was expected to be the region of
greatest change in a study of subjects with medial disease, but
within themedial compartment changemay vary between knees18,
likely due to the individual mechanical and/or biological condi-
tions. However, it is well known that, in general OA populations,
knees preferentially show cartilage loss in the medial or lateral
femorotibial compartment, and that limb alignment is the main
determinant of medial vs lateral progression17,19e22. A recent
DMOAD study comparing the sparing effects of licofelone and
naproxen in OA deﬁned loss of cartilage volume in the MEDIAL
femorotibial compartment as the primary efﬁcacy outcome
measure23. Although this primary outcomemeasurewas reached in
this study, the authors reported the protective effect of licofelone to
act predominantly in the LATERAL femorotibial compartment. The
“extended” OV approach presented here can overcome this chal-
lenge in the context of clinical trials23,38, as it does not require one
to deﬁne the primary outcome “a priori” in terms of a speciﬁc
compartment, cartilage plate or subregion. This not only permitsone to widen inclusion criteria during screening for a clinical trial
(i.e., to include knees with either medial or lateral disease), but also
to generalize the results by allowing one to examine a general OA
cohort with few restrictions.
The results from the current study show that the spatial origin of
OV1 is heterogeneously distributed across the joint, but that some
subregions are more frequently involved (e.g., ccMF and cLT) than
others (i.e., no random distribution). This heterogeneous distribu-
tion provides one of the reasons why OV1 is more sensitive to
differences (in the rate of change) between groups than region-
speciﬁc analyzes. The current study therefore shows for the ﬁrst
time that, when using an eOV approach, the level of sensitivity in
differentiating rates of progression between JSN and no-JSN knees
is substantially increased over radiography, the analysis of total
cartilage plates and compartments, and the analysis of anatomi-
cally deﬁned subregions. Additional statistical power may be
gainedwhen “a priori” deﬁning OV1 alone as a primary outcome, or
when averaging results over a group of orders (i.e., 1e4). Averaging
changes in cartilage thickness for orders 1e4, however, did not
provide lower P-values between JSN and no-JSN knees than OV1
alone (data not shown). The results of the current study thus
indicate that, in context of baseline radiographic JSN, eOV1 is the
most effective measure in determining differences in rates of
cartilage loss. Further studies are required to determine whether
this is also true for other risk factors of OA progression, or for
treatment with speciﬁc DMOADs. If a DMOAD is primarily targeted
at reducing cartilage loss, however, OV1 may potentially be used as
an effective and powerful “single” outcome measure, whereas
deﬁnition of a region-based outcome (compartment, plate or
subregion) may involve greater needs (and costs) for selecting
speciﬁc knees, and/or may increase the risk of study failure.
Because of its potential for higher statistical power (both with and
without correction for multiple testing), the OV approach may
become a valuable tool for reducing the number of participants or
the observation time in a clinical trial, without unnecessarily
sacriﬁcing the generality of the ﬁndings.
In conclusion, an eOV approach, based on medial and lateral
femorotibial subregions, showed a higher discriminatory power
than radiography, region-based approaches with MRI, and mOVs
when comparing longitudinal cartilage thickness changes in knees
with and without baseline JSN in knees from the OAI. Because the
(extended) OV approach removes the link between the magnitude
and location of change, it allows for the inclusion of knees with
both medial and lateral disease, and of knees with different
biomechanical risk factors inﬂuencing the load distribution within
the femorotibial joint. As this circumvents the challenge of select-
ing a particular knee compartment or anatomical subregion as an
outcome measure of progression “a priori”, the approach may
generally provide a powerful tool in studies targeting risk factor
identiﬁcation or treatment efﬁcacy in OA.
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